Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX for Platysma Prominence
NCT04949399Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2021
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in platysma prominence comparing BOTOX with Placebo (2 arms). Primary endpoints: Number of Participants With Adverse Events at Day 120, Composite Achievement of Grade 1 or 2 and >=2 Grade Improvement on C-APPS and P-APPS at Day 14 and 2 more. Started Jul 2021; status: completed.
02
Drugs
botulinum toxin
03
Conditions
platysma prominence
Beyond the preview
Go deeper on NCT04949399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04949399.